Accelerating precision medicine™

Neo-epitope Direct: Discovery and Characterization of Tumor Antigens and Novel T-Cell Epitopes

By combining over a decade of experience in proteomics and in immune monitoring, Caprion offers a more efficient way to identify and characterize tumor antigens and novel T-cell epitopes. Caprion leverages the sample preparation, mass spectrometry, and data analysis expertise of its ProteoCarta division to isolate MHC complexes from tissue, directly identify MHC peptides presented in vivo, and select peptides that are the most upregulated in tumor (including mutations and other variants) for further characterization. Our ImmuneCarta division uses those peptide candidates to activate PBMCs from the same patient and characterize the immune response including phenotype, activation state, and reactivity. Learn more about our process here.


Accelerate your immune oncology and vaccine programs by leveraging the combined expertise of our ProteoCarta and ImmuneCarta divisions to support:

  • Therapeutic cancer vaccines
  • Adoptive T-cell therapies
  • Target validation

Benefits of Caprion's Approach

Caprion’s approach to identification and characterization of tumor antigens and novel T-cell epitopes provides:

  • Direct identification of naturally-processed peptides presented by MHC complexes isolated from tissue
  • Elimination of reliance on epitope modeling, leading to lower attrition rates
  • Fewer and higher quality peptide candidates for follow-up
  • Identification of tumor-associated sequence variants (point mutations, deletions, insertions etc.)
  • Increased coverage of different HLA types
  • Comprehensive characterization of T-cell response, including phenotyping and functional assays